Imugene Limited is a biotechnology company specializing in the development of innovative immunotherapies for cancer treatment. The company focuses on harnessing the immune system to target and destroy cancer cells through its proprietary platforms, including oncolytic virotherapy and B-cell immunotherapy. Imugene generates revenue primarily through partnerships, licensing agreements, and research funding, aiming to bring its therapies to market. Founded in 2012 and headquartered in Australia, it has gained recognition for its clinical trials and collaborations with leading research institutions. Candidates should note its commitment to cutting-edge cancer therapies and its growing global presence in the biotech industry.